A Study of Apabetalone in Subjects With Long -COVID

Exclusion Criteria

• •9. Subjects with chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) \<25 mL/min/1.73 m2
• •10. New York Heart Association Class IV congestive heart failure
• •11. Evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure; chronic liver diseases such as primary biliary cholangitis, untreated hemochromatosis, and primary sclerosing cholangitis
• •12. Subject meets any of the following laboratory criteria at Screening:
• •* Alanine transaminase (ALT) or aspartate transaminase (AST) values \> 1.5x the upper limit of normal (ULN)
• •* Total bilirubin \>1.5 × ULN.
• •* Evidence of an active hepatitis B virus or hepatitis C virus infection
• •* History of a positive test for human immunodeficiency virus (HIV)
• •13. Subjects taking concomitant cytochrome P450 3A4 strong inducers and/or strong inhibitors, or corticosteroid use \>10 mg daily prednisone or equivalent.
• •14. Subjects who have received a COVID-19 vaccine or booster in the last 30 days prior to screening (Visit 1).
• •15. Subject who have participated in a clinical study and received any investigational medication within the last 30 days prior to screening (Visit 1).
• •16. Female subjects who are pregnant, planning to get pregnant, lactating/breastfeeding, or has a positive urine pregnancy test at the Screening Visit or prior to enrollment at the Day 1 visit.
• •17. Subjects whose safety may be compromised by study participation or are not, in the opinion of the investigator, able or willing to comply with the protocol.